12 citations
,
May 2023 in “Molecules” Polygoni Cuspidati Rhizoma et Radix contains compounds that inhibit certain enzymes.
September 2016 in “Journal of Dermatological Science” A gene mutation worsens skin irritation in mice due to a lack of certain fats.
66 citations
,
January 2008 in “Pharmacology Biochemistry and Behavior” AC-5216 reduces anxiety in mice through neurosteroids affecting GABAA receptors.
March 2025 in “Journal of Science Natural Science” Acetyl tetrapeptide-3 was successfully made for use in hair loss treatments.
3 citations
,
November 2019 in “Journal of the ASEAN Federation of Endocrine Societies” A 20-year-old woman with a rare form of Turner syndrome showed improvement with hormonal therapy and needs comprehensive care.
November 2022 in “Zenodo (CERN European Organization for Nuclear Research)” April 2016 in “Journal of Investigative Dermatology” Mutations in the TSPEAR gene cause a new form of ectodermal dysplasia affecting hair and tooth development.
October 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Early genetic testing and zinc therapy are crucial for managing acrodermatitis enteropathica effectively.
December 2025 in “Dermatology Reports” Topical ruxolitinib quickly improves non-segmental vitiligo.
41 citations
,
February 2021 in “Cureus” Proxalutamide helps COVID-19 patients get rid of the virus faster and recover quicker.
25 citations
,
February 2013 in “The journal of investigative dermatology/Journal of investigative dermatology” Blocking SCD1 in the skin with XEN103 shrinks sebaceous glands in mice.
7 citations
,
April 2012 in “Clinical investigation” Transdermal testosterone can improve sexual desire in postmenopausal women but lacks long-term safety data and is not FDA-approved for this use.
November 2025 in “International Journal of Innovative Research and Scientific Studies” Regenera Activa AMT effectively improves hair growth and reduces hair loss in androgenetic alopecia.
April 2023 in “Journal of Investigative Dermatology” The document's conclusion cannot be provided because the content is not accessible.
November 2025 in “International Journal of Research in Medical Sciences” Titagen® improves skin, hair, nail health, and reduces osteoarthritis symptoms safely.
2 citations
,
November 2022 in “Skin research and technology” 5% topical minoxidil improves hair density and quality in monilethrix patients.
9 citations
,
February 2018 in “Journal of dermatological treatment” Methotrexate improved skin condition in 64% of patients with generalized granuloma annulare.
March 2026 in “Pharmaceuticals” Xiaoban Kangfu capsules contain compounds that may help with antioxidants, reducing inflammation, and promoting hair growth.
April 2018 in “Journal of Investigative Dermatology” High amphiregulin in the skin is a bad sign for acute graft-versus-host disease.
2 citations
,
July 2015 in “Journal of Cosmetic Dermatology” No clear link between specific gene and hair loss in Mexican brothers.
January 2007 in “Revista del Centro Dermatológico Pascua” A 2-year-old boy was diagnosed with a rare genetic condition causing fragile hair, intellectual issues, and short stature.
November 2008 in “Hair transplant forum international” The document's conclusion cannot be determined.
2 citations
,
July 2011 in “AFRICAN JOURNAL OF BIOTECHNOLOGY” Seven genetic variations in sheep's DSG4 gene are linked and affect wool traits.
28 citations
,
November 2018 in “Journal of Cellular and Molecular Medicine” CXXC5 is a protein that controls cell growth and healing processes, and changes in its activity can lead to diseases like cancer and hair loss.
39 citations
,
November 2021 in “Clinical Endocrinology” Testosterone replacement is recommended for men with low testosterone levels and symptoms of hypogonadism.
18 citations
,
October 2005 in “International Journal of Pharmaceutics” Adding a small amount of TPGS to minoxidil can help hair growth, but too much TPGS reduces this effect and increases minoxidil in the blood.
December 2024 in “Journal of Medicinal Chemistry” A new topical treatment for hair loss shows promise by targeting androgen receptors.
12 citations
,
May 2010 in “Journal of Clinical Oncology” MK-5108 is safe and shows potential against tumors, especially alone.
5 citations
,
March 2020 in “Thoracic Cancer” CT-707 is effective and safe for treating certain Chinese lung cancer patients.
1 citations
,
May 2025 in “Frontiers in Medicine” This retrospective case series evaluated the efficacy and safety of dual-targeted therapy (DTT) in 18 patients with refractory inflammatory bowel disease (IBD) across three tertiary hospitals in China. The study included 8 patients with ulcerative colitis and 10 with Crohn’s disease, using combinations of biologic agents and tofacitinib. Results showed high clinical response rates of 88.23% at 3 months, 91.67% at 6 months, and 100% at 9 months, with an endoscopic response in 88.89% of evaluated patients at 9 months. Adverse events were minimal, with some patients experiencing ustekinumab-associated arthralgia and alopecia, and tofacitinib-related allergic purpura, leading to a transition to monotherapy. Two patients developed infections but continued DTT after treatment. The study concludes that DTT is a promising and safe option for patients unresponsive to conventional monotherapies.